Search Results for "Atterocor Web Site"
Matching Channels
Ras is the first protein in the apoptosis cascade
Ras is the first protein in the apoptosis cascade, activated by tyrosine kinase receptors in response to growth factor stimulation from the extra cellular matrix. Ras is an oncogene, meaning it prom...
Caspases are a family of enzymes with very specific characteristics that can be used in almost every biological pathway in the body. The knock-on effects of the action of caspases keep us alive, ini...
Interleukin 1 IL 1 Receptor IL 1R
Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...
Anthrax Vaccines and Therapeutics
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synth...
Matching News
Atterocor debuts with $16 million
Newco Atterocor Inc. (Ann Arbor, Mich.) debuted on Friday with $16 million in a series A round led by Frazier Healthcare and 5AM Ventures. Atterocor is developing therapies to treat adrenal cancer. Th...
[Atterocor] launches, raises $16.6mm in Series A round
[Atterocor Inc.] (adrenal cancer drug discovery) has raised $16.6mm through its Series A round. Frazier Healthcare and 5AM Ventures led and were joined by two additional undisclosed investors. The co...
Atterocor Lands $16M Series A Round For Cancer Therapy
Ann Arbor, MI-based Atterocor announced Friday that it has raised $16 million in a Series A round led by Frazier, based in Seattle and Menlo Park, CA, and 5am Ventures, based in Waltham, MA and Menl...
Michigan startup Atterocor raises $16 million for adrenal cancer therapy
Ann Arbor, Michigan-based startup Atterocor benefitted from recent increased interest in health care venture capital investment in the Midwestern US with a $16 million Series A financing round to kick...
Atterocor, Inc., a company developing an innovative therapy for adrenal cancer, today announced a $16 million Series A venture capital financing. Frazier Healthcare and 5AM Ventur...
Atterocor completes venture financing
Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure
Plus news on recent financial activity by Mersana Therapeutics, Hyperion Therapeutics, Atterocor and Exelixis.
R&D, East & West: Lilly invests in its global research network
Eli Lilly officially opened its new research facilities at its R&D base in Erl Wood in Surrey in April. The site near Woking in the south of England is the pharma company’s biggest R&D site...
Matching PubMed Articles
The effect of inorganic phosphate (P(i)) on uni-site ATP binding and hydrolysis by the nucleotide-depleted F(1)-ATPase from beef heart mitochondria (ndMF(1)) has been investigated. It is shown for the...
Glycogen synthase is a rate-limiting enzyme in the biosynthesis of glycogen and has an essential role in glucose homeostasis. The three-dimensional structures of yeast glycogen synthase (Gsy2p) comple...
On the launch-site effect for skipped words during reading.
The launch-site effect, a systematic variation of within-word landing position as a function of launch-site distance, is among the most important oculomotor phenomena in reading. Here we show that the...
A new method for environmental site assessment of urban solid waste landfills.
Regarding various types of pollutant, waste management requires high attention. Environmental site selection study, prior to landfill operation, and subsequently, monitoring and maintaining of the loc...
Ferritins are ubiquitous iron storage proteins. Recently, we identified a novel metal-binding site, transit site, in the crystal structure of phytoferritin. To elucidate the function of the transit si...